Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
25
pubmed:dateCreated
1995-2-27
pubmed:abstractText
Ribozymes offer a potentially important way to inactivate intracellular RNA from almost any gene whose nucleotide sequence is known. Recently, we found that hammerhead ribozymes directed against mRNA of tumour necrosis factor alpha (TNF alpha) and its derivatives, preferentially bind to a cellular protein(s). To better understand the effect of different 3'-terminal hairpins on ribozyme stability as well as their effect on the protein binding to the ribozyme, a mathematical treatment of the decay of three TNF alpha ribozymes that differed at their 3' ends was performed. One ribozyme contained a 3'-terminal hairpin derived from a transcription terminator of bacteriophage T7, another contained the same hairpin but modified to be highly enriched for G+C nucleotides, and a third lacked a hairpin. The TNF alpha ribozyme decay had two kinetic components. The slow component exhibited exponential decay with a half life of approximately 250 h in all cases. The 3'-terminal hairpin has no significant effect on this component. This slow phase accounted for 60-80% of ribozyme decay. The rapid phase also exhibited exponential decay. For this phase, a 3'-terminal hairpin roughly doubled the half-life (1.7-3.4). The slow phase of degradation was about three times faster for a ribozyme directed at the integrase mRNA of human immunodeficiency virus-1 than that seen with the TNF alpha ribozyme. Taken together, these results suggest that the ribozyme population is initially sensitive to degradation, with the presence of a hairpin provides some protection, and indicate that the addition of the hairpin to the ribozyme did not prevent the in vivo additional stabilizing effect of the protein(s).
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1373488, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1381347, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1408757, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1422085, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1438280, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1529527, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1538398, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1660142, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1692327, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1738200, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1821646, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1871136, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1895402, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-1946436, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-2107573, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-2183177, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-2436805, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-2438771, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-2440339, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-2457170, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-2684648, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-3315856, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-3526287, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-537910, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-6392892, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-7516239, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-7932719, http://linkedlifedata.com/resource/pubmed/commentcorrection/7838709-8327516
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0305-1048
pubmed:author
pubmed:issnType
Print
pubmed:day
25
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5571-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
In vivo decay kinetic parameters of hammerhead ribozymes.
pubmed:affiliation
Institute of Immunology and Rheumatology, Rikshospitalet, Oslo, Norway.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't